Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 6/20 | 0.35 |
| ▸ | GCK | P35557 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8749676 | 0.84 | GRN (0.40) | CTSSCTSKUSP30CTSLCTSB | |
| SCHEMBL6121423 | 0.84 | GRN (0.40) | CTSSCTSKUSP30CTSLCTSB | |
| SCHEMBL6120738 | 0.84 | CNR2 (0.38) | CTSSCTSKUSP30AAK1CTSL | |
| SCHEMBL8749679 | 0.84 | CNR2 (0.38) | CTSSCTSKUSP30AAK1CTSL | |
| SCHEMBL20218495 | 0.84 | CTSS (0.37) | CTSSCTSKUSP30AAK1CTSL | |
| SCHEMBL16800 | 0.78 | CTSK (0.53) | CTSSCTSKAAK1CTSL | |
| SCHEMBL2199576 | 0.78 | CTSK (0.53) | CTSSCTSKAAK1CTSL | |
| SCHEMBL2199572 | 0.78 | CTSK (0.53) | CTSSCTSKAAK1CTSL | |
| SCHEMBL16774 | 0.76 | CTSS (0.57) | CTSSCTSKAAK1CTSLCTSB | |
| SCHEMBL16773 | 0.76 | CTSS (0.57) | CTSSCTSKAAK1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | CTSS 917/4885CTSK 2116/4885USP30 2866/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | CTSS 917/4885CTSK 2116/4885USP30 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.